Research programme: hydroxypatite-interferon - LTT Bio-PharmaAlternative Names: HAp-IFN
Latest Information Update: 07 Oct 2015
At a glance
- Originator LTT Bio-Pharma
- Class Interferons
- Mechanism of Action Interferon modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 10 May 2010 Early research in Hepatitis C in Japan (unspecified route)